MS Speaks
Multiple Sclerosis => TREATMENTS => OCREVUS (ocrelizumab) => Topic started by: agate on May 25, 2017, 05:58:45 am
-
This may very well be a Tysabri problem. A patient who'd been taking Tysabri for 3 years switched to the new drug, Ocrevus. After a month on it the patient developed PML, according to this news release:
http://www.nasdaq.com/article/roche-investigating-case-of-patient-illness-after-taking-ms-drug-20170524-01087 (http://www.nasdaq.com/article/roche-investigating-case-of-patient-illness-after-taking-ms-drug-20170524-01087)
Just when the patient stopped taking Tysabri isn't stated.
-
More on this in Multiple Sclerosis News Today, May 25:
https://multiplesclerosisnewstoday.com/2017/05/25/pml-detected-in-ocrevus-treated-patient-previously-treated-with-tysabri-for-3-years/ (https://multiplesclerosisnewstoday.com/2017/05/25/pml-detected-in-ocrevus-treated-patient-previously-treated-with-tysabri-for-3-years/)